 Amgen Inc. AMGN, 1.32 said Thursday it plans to buy ChemoCentryx Inc. CCXI, 3.61 for 3.7 billion in cash. The deal will give Amgen access to Tavneos, a treatment for ANCA-associated vasculitis that received approval from the Food and Drug Administration in October. 